Entellus Medical Inc. (ENTL) Receives New Coverage from Analysts at Deutsche Bank AG
Deutsche Bank AG started coverage on shares of Entellus Medical Inc. (NASDAQ:ENTL) in a report released on Thursday. The brokerage issued a buy rating and a $26.00 price target on the medical technology company’s stock.
A number of other analysts have also recently commented on ENTL. BTIG Research started coverage on shares of Entellus Medical in a research note on Tuesday, June 14th. They set a buy rating and a $22.00 target price for the company. Canaccord Genuity reissued a buy rating and set a $23.00 target price on shares of Entellus Medical in a research note on Wednesday, June 29th. Bank of America Corp. reissued a buy rating on shares of Entellus Medical in a research note on Monday, July 18th. Finally, Zacks Investment Research raised shares of Entellus Medical from a hold rating to a buy rating and set a $20.00 target price for the company in a research note on Monday, August 8th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $22.75.
Entellus Medical (NASDAQ:ENTL) traded down 2.324% during mid-day trading on Thursday, reaching $21.225. 38,144 shares of the company were exchanged. The company’s market capitalization is $400.07 million. Entellus Medical has a 1-year low of $13.72 and a 1-year high of $22.57. The company has a 50 day moving average of $19.81 and a 200-day moving average of $18.04.
Entellus Medical (NASDAQ:ENTL) last released its quarterly earnings data on Wednesday, August 3rd. The medical technology company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.08. Entellus Medical had a negative net margin of 33.54% and a negative return on equity of 41.83%. The company earned $18.73 million during the quarter, compared to analysts’ expectations of $18.48 million. During the same quarter in the previous year, the company earned ($0.15) earnings per share. The firm’s revenue for the quarter was up 23.3% on a year-over-year basis. On average, equities research analysts forecast that Entellus Medical will post ($1.23) EPS for the current year.
In related news, Director Brian E. Farley sold 30,000 shares of the business’s stock in a transaction dated Wednesday, October 5th. The shares were sold at an average price of $22.26, for a total transaction of $667,800.00. Following the transaction, the director now directly owns 514,581 shares in the company, valued at $11,454,573.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP James D. Surek sold 10,000 shares of the business’s stock in a transaction dated Thursday, September 8th. The stock was sold at an average price of $18.71, for a total transaction of $187,100.00. Following the transaction, the vice president now owns 95,031 shares in the company, valued at $1,778,030.01. The disclosure for this sale can be found here. Insiders own 9.10% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the company. Murphy Michael R raised its position in Entellus Medical by 810.2% in the first quarter. Murphy Michael R now owns 482,137 shares of the medical technology company’s stock worth $8,770,000 after buying an additional 429,166 shares during the last quarter. Cortina Asset Management LLC raised its position in Entellus Medical by 39.2% in the second quarter. Cortina Asset Management LLC now owns 421,897 shares of the medical technology company’s stock worth $7,708,000 after buying an additional 118,745 shares during the last quarter. BlackRock Fund Advisors raised its position in Entellus Medical by 40.1% in the second quarter. BlackRock Fund Advisors now owns 195,518 shares of the medical technology company’s stock worth $3,572,000 after buying an additional 55,996 shares during the last quarter. State Street Corp raised its position in Entellus Medical by 89.2% in the second quarter. State Street Corp now owns 96,040 shares of the medical technology company’s stock worth $1,753,000 after buying an additional 45,267 shares during the last quarter. Finally, Spark Investment Management LLC acquired a new position in Entellus Medical during the first quarter worth $440,000. Hedge funds and other institutional investors own 66.22% of the company’s stock.
About Entellus Medical
Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation.
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.